Respiratory Conditions, With The Exception Of Pneumonia

Respiratory Conditions; In this study the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommend that use of bacterial lysate medicines; which are authorize for the treatment of respiratory conditions, be restrict to the prevention of recurrent respiratory infections, with the exception of pneumonia. Bacterial lysate medicines should not be prescribe for the treatment of existing respiratory infections or for prophylaxis of pneumonia, owing to lack of efficacy data, the CHMP said.

The Respiratory Conditions

Respiratory illness is a common problem in the United States. Many times, people are genetically more likely to get respiratory conditions; but your work place or environmental exposures could also play a big role. One thing is for sure, smoking is the most common cause of respiratory disease. Unity Point Health pulmonologist, Jim Meyer, DO, tells us the top eight respiratory system illnesses, including which two are the most dangerous.

Chronic obstructive pulmonary disease is an umbrella term; so that encompasses several respiratory illnesses that cause breathlessness, or the inability to exhale normally. People usually experience symptoms, including shortness of breath, and normally cough up sputum (mucus from the lungs), especially in the morning.

The recommendation follows a review of bacterial lysate medicines; so by the committee that was launch last June at the request of Italy. At the time, the EMA said, “Recent studies have cast doubt on the effectiveness of bacterial lysate medicines in reducing the number and severity of respiratory infections in adults; also children who experience repeat infections. In addition, in very rare cases, these medicines are known to cause serious side effects relate to the immune system.”

Prevention of pneumonia

The CHMP review found “no robust data showing that these medicines; which are effective at treating existing respiratory infections, or for the prevention of pneumonia; so therefore they should not use for these purposes,” the EMA said in a news release. Although data are limited, the review find some evidence of effectiveness; which of bacterial lysate medicines for preventing recurrent respiratory tract infections. In addition, the safety profile of these drugs was in line with what is expect for this type of product, the EMA said.

In their review, the committee consider results of safety and efficacy data; so from clinical trials and advice from infectious disease experts. The prescribing information of bacterial lysate medicines will be update with the new indication; also with a warning against use for prevention of pneumonia, the EMA said. Use of bacterial lysate medicines for the prevention of recurrent respiratory infections “can continue; but the companies must provide further data on safety and effectiveness from new clinical studies by 2026,” the EMA said.